Tobacco dependence treatment guidelines

Czech version

Authors: Eva Králíková ^1,2,3; Richard Češka ^4,5; Alexandra Pánková ^1,2,3; Lenka Štěpánková ^1,3; Kamila Zvolská ^1,3; Vladislava Felbrová ^1,3; Stanislava Kulovaná ¹; Miroslav Zvolský ⁶
Authors‘ workplace: Centrum pro závislé na tabáku III. interní kliniky – kliniky endokrinologie a metabolizmu 1. LF UK a VFN Praha přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA ¹; Ústav hygieny a epidemiologie 1. LF UK a VFN Praha, přednosta doc. MUDr. Milan Tuček, CSc. ²; Společnost pro léčbu závislosti na tabáku Praha, předsedkyně doc. MUDr. Eva Králíková, CSc. ³; Centrum preventivní kardiologie III. interní kliniky – kliniky endokrinologie a metabolizmu 1. LF UK a VFN Praha přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA ⁴; Česká internistická společnost České lékařské společnosti J. E. Purkyně, předseda prof. MUDr. Richard Češka, CSc., FACP, FEFIM ⁵; Ústav zdravotnických informací a statistiky ČR Praha, ředitel doc. RNDr. Ladislav Dušek, Ph. D. ⁶
Published in: Vnitř Lék 2015; 61(Suppl 1): 3-15
Category: Guidelines

Overview

Tobacco dependence causes every sixth death in the Czech Republic and is associated with diseases of the whole body. Treatment of tobacco dependence should be a standard part of clinical care to the extent of time available – from brief intervention at each clinical contact with patients up to intensive treatment. It includes psycho-socio-behavioural support and pharmacotherapy. It should apply to all professions in clinical medicine – as recommended by WHO mainly doctors, nurses, pharmacists and dentists, and should be covered within health care systems. Economically, it is one of the most cost-effective interventions in medicine. In our population over 15 years about 30 % smokes (about 2.2 million people), diagnosis F17 relates to approximately 1.75 million people (about 80 % of smokers).

Key words:
doctors – health care professions – nurses – pharmacists – practice guideline – tobacco dependence – treatment

Sources

1. Peto R, Lopez AD, Boreham J et al. Mortality from smoking in developed countries 1950–2005 (or later) (update March 2012). Oxford University Press: Oxford. Dostupné z WWW: <http://www.ctsu.ox.ac.uk/~tobacco/>.

2. International Statistical Classification of Diseases and Related Health Problems. 10th revision: ICD-10. World Health Organization (WHO): Geneva 1992. Dostupné z http: <http://apps.who.int/classifications/icd10/browse/2015/en>.

3. Diagnostic and Statistical Manual of Mental Disorders. 5th ed: DSM-5. American Psychiatric Association: Washington (DC) 2013. ISBN 978–0890425558. Dostupné z WWW: <http://www.psychiatry.org/practice/dsm>.

4. Csémy L, Sovinová H, Sadílek P. Užívání tabáku v České republice 2013. SZÚ Praha 2014. Dostupné z WWW: <http://www.szu.cz/uploads/documents/czzp/CPVZ_aktualne/Tabak_Sovinova/UzivaniTabaku2013.pdf>.

5. Fiore MC, Jaén CR, Baker TB et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. US Department of Health and Human Services: Rockville (MD) 2008. Abstractum. Dostupné z WWW: <http://www.ncbi.nlm.nih.gov/books/NBK63952/>.

6. World Health Organization (WHO): MPOWER. Tobacco Free Iniciative (TFI). Dostupné z WWW: <http://www.who.int/tobacco/mpower/en/>.

7. World Bank. Curbing the epidemic – governments and the economics of tobacco control (English). World Bank: Washington DC 1999. Dostupné z WWW: <http://documents.worldbank.org/curated/en/1999/05/437174/curbing-epidemic-governments-economics-tobacco-control>.

8. World Health Organization: Framework Convention on Tobacco Control, WHO – Rámcová úmluva o kontrole tabáku WHO. Dostupné z WWW: <http://www.fctc.org>.

9. Heatherton F, Kozlowski LT, Frecker RC et al. The Fagerström test for nicotine dependence: A revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991; 86(9): 1119–1127.

10. Fagerström K. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. Nicotine Tob Res 2012; 14(1): 75–78.

11. West R, Hajek P, Stead L et al. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005; 100(3): 299–303.

12. Brown J, Beard E, Kotz D et al. Real-world effectiveness of e-cigarettes when used to aid smoking cessation: a cross-sectional population study. Addiction 2014; 109(9): 1531–1540.

13. Cahill K, Stevens S, Perera R et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis.Cochrane Database Syst Rev 2013; 5: CD009329. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD009329.pub2>.

14. Hartmann-Boyce J, Stead LF, Cahill K et al. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews. Addiction 2014; 109(9): 1414–1425.

15. Kralikova E, Kmetova A, Stepankova L et al. Fifty-two-week continuous abstinence rates of smokers being treated with varenicline versus nicotine replacement therapy. Addiction 2013; 108(8): 1497–1502.

16. Zwar N, Richmond R, Borland R et al. Supporting smoking cessation: a guide for health professionals. The Royal Australian College of General Practitioners: Melbourne 2011. ISBN 978–0–86906–331–6. Dostupné z WWW: <http://www.treatobacco.net/en/uploads/documents/Treatment%20Guidelines/Australia%20treatment%20guidelines%20in%20English%202011.pdf>.

17. The New Zealand Guidelines to Help People to Stop Smoking. Update September 14, 2014. ISBN 978–0-478–42809–4 (print), 978–0-478–42810–0 (online). Dostupné z WWW: <http://www.health.govt.nz/publication/new-zealand-guidelines-helping-people-stop-smoking>.

18. Hurt RD, Ebbert JO, Hays JT et al. Treating tobacco dependence in a medical setting, CA Cancer J Clin 2009; 59(5): 314–326.

19. Králíková E, Kmeťová E, Felbrová V et al. Centra pro závislé na tabáku v České republice v roce 2012: přehled, ekonomika. Čas Lék Čes 2014; 153(5): 246–252.

20. Croghan IT, Offord KP, Evans RW et al. Cost-effectiveness of treating nicotine dependence: the Mayo Clinic experience. Mayo Clin Proc 1997; 72(10): 917–924.

21. Flack S, Taylor M, Trueman P et al. NICE. Cost-effectiveness of Interventions for Smoking Cessations. York Health Economics Consortium 2007. Final report. NICE and The University of York: 2007. Dostupné z WWW: <https://www.nice.org.uk/guidance/ph10/evidence/smoking-cessation-services-economics-modelling-report-2>.

22. Shields PG, Herbst ES, Davis J et al. NCCN Clinical Practice Guidelines in Oncology. Smoking Cessatio. Version I.2015. Dostupné z WWW: <http://cancer.osu.edu/~/media/Files/Shared/Press-Releases/Cancer/2015/NCCN-smoking-cessation-guideline.pdf?la=en>.

23. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003; 290(1): 86–97.

24. Twardella D, Küpper-Nybelen J, Rothenbacher D et al. Short-term benefit of smoking cessation in patients with coronary heart disease: estimates based on self-reported smoking data and serum cotinine measurements. Eur Heart J 2004; 25(23): 2101–2108.

25. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation 2005; 111(20): 2684–2698.

26. Meyers DG, Neuberger JS, He J. Cardiovascular effect of bans on smoking in public places: a systematic review and meta-analysis. J Am Coll Cardiol 2009; 54(14): 1249–1255.

27. Yoon U, Kwok LL, Magkidis. Efficacy of lifestyle interventions in reducing diabetes incidence in patients with impaired glucose tolerance: a systematic review of randomized controlled trials. Metabolism 2013; 62(2): 303–314.

28. Hunt JJ, Cupertino AP, Gajewski BJ et al. Staff commitment to providing tobacco dependence in drug treatment: Reliability, validity, and results of a national survey. Psychol Addict Behav 2014; 28(2): 389–395.

29. Pisinger Ch. Smoking cessation in psychiatry: Is there sufficient evidence to recommend smoking cessation activities? A review of the literature. Network of Health Promoting Hospitals in Denmark: Copenhagen 2007. ISBN: 978–87–91688–09–6. Dostupné z WWW: <http://ensh.aphp.fr/IMG/pdf/DK-Mental_health_workshop_report.pdf>.

30. Hansen K. Four Myths About Smokers With Behavioral Health Conditions. California Smokers’Helpline. Dostupné z WWW: <http://info.nobutts.org/blog/bid/128426/Four-Myths-About-Smokers-With-Behavioral-Health-Conditions>.

31. Kalman D, Di Girolamo KS, Smelson G et al. Addressing tobacco use disorder in Smokers in early remission from alcohol dependence: the case for integrating smoking cessation Services in substance use disorder. Treatment programs. Clin Psychol Rev 2010; 30(1): 12–24.

32. Wong J, Lam DP, Abrishami A et al. Short-term preoperative smoking cessation and postoperative complications: a systematic review and meta-analysis. Can J Anaesth 2012; 59(3): 268–279.

33. Mala K, Felbrova V, Kulovana S et al. Smoking cessation guidelines for nurses. The Society for Treatment of Tobacco Dependence and The Czech Association of Nurses (in Czech). 2010. Dostupné z WWW: <http://www.slzt.cz/odborna-doporuceni>.

34. Sarna L, Bialous SA, Nandy K et al. Changes in smoking prevalences among health care professionals from 2003 to 2010–2011. JAMA 2014; 311(2): 197–199.

35. Kavalírová L et al. Doporučený postup – odvykání kouření. Česká lékárnická komora 2010. Dostupné z WWW: <http://lekarnici.cz/Pro-verejnost/PORADENSTVI-KONZULTACE/PORADENSTVI-KONZULTACE/Doporuceny-postup-Odvykani-koureni.aspx>.

36. Hughes JR. The effects of abstinence from tobacco: Valid symptoms and time course. Nicotine Tob Res 2007; 9(3): 315–27. Dostupné z WWW: <http://www.uvm.edu/~hbpl/?Page=minnesota/default.html>.

Labels

Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

2015 Issue Suppl 1